Neuronetics Insider Buying Surge Signals Management’s Bet on Turnaround – CEO Purchases 1.06M Shares at Deep Discount to Boost Confidence in NeuroStar Revenue Growth

Insider Buying Spurs Optimism at Neuronetics

The latest Form 4 filing reveals that owner Chernett Jorey purchased 607,400 shares on March 18 and an additional 450,000 on March 19, bringing her stake to 8,573,804 shares. The shares were bought at an average price of roughly $1.35—well below the closing price of $1.515 on the day of the transaction. This “buy‑side” activity occurs amid a broader wave of insider purchases, including a March 4 buy by EVP William Macan, and follows a series of sales by senior executives in February. The contrast between the recent buying spree and earlier selling suggests that insiders are now betting on a turnaround in the company’s earnings trajectory.

What This Means for Investors

Neuronetics’ market cap of $86.98 million and a current P/E ratio of –1.78 indicate that the company is still operating at a loss. Nevertheless, the quarterly report highlighted a significant revenue uptick driven by the NeuroStar therapy system, and operating losses are narrowing. Insider purchases, especially at prices below market, can be interpreted as confidence signals that management believes the stock is undervalued or poised for a rebound. For shareholders, this may translate into a modest lift in the share price and a potential shift in sentiment toward the company’s growth prospects. However, the lack of social‑media buzz and a neutral sentiment score suggest that the broader investor community remains cautious.

Profile of Chernett Jorey

Chernett Jorey’s transaction history shows a pattern of incremental buying. In the week before the current purchase, she bought 531,000 shares at $1.16 on March 17, raising her holding to 7,516,404 shares. Her recent acquisitions total 1,057,400 shares, bringing her stake to 8,573,804—an increase of about 14 % from the previous week. The consistency in buying across multiple days and the willingness to purchase at discounted prices suggest a long‑term investment horizon and confidence in Neuronetics’ product pipeline. Unlike some executives who have sold significant portions of their holdings, Chernett has maintained a steadily growing position, indicating a more optimistic outlook for the company’s future.

Implications for Neuronetics’ Future

The current insider buying, coupled with the company’s expanding revenue base, signals a potential shift toward profitability. If the NeuroStar system continues to capture market share, the company could see a reduction in operating losses and improved cash flow, providing the runway for further R&D investment. For investors, the insider activity offers a subtle endorsement of the company’s strategy, but it should be weighed against the broader context of a declining P/E and a sector that remains highly competitive. Staying attuned to future insider filings and quarterly results will be key to assessing whether this buying trend translates into sustained shareholder value.